First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Biogen Inc. (BIIB): the developments shaping its investment case

    Follow the evidence affecting Biogen Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Biogen Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-14 · 4 reports
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    Channel: Increased competition in the Spinal Muscular Atrophy (SMA) market, potential erosion of market share for Spinraza.
    Bearish· 3-12m
    2026-09-01
    Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
    Channel: Increased competition in the multiple sclerosis market from a potentially superior oral BTK inhibitor could erode market share for existing and pipeline MS therapies.
    Bearish· 1-5y
    2026-09-01
    Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
    Channel: Increased competition in the multiple sclerosis market, particularly for oral therapies. Potential market share erosion for existing MS drugs.
    Bearish· 1-5y

    Event impact log

    40 events mapped to BIIB since 2026-08-14. Evidence through 2026-09-29.

    DateEventChannelDirectionHorizonImpact
    2026-09-29Oncolytics Biotech Inc Announces Publication of Pelareorep Liver Cancer DataIndirectly, as a large biotechnology company with an oncology pipeline, general positive sentiment or validation of novel therapeutic approaches in cancer could have a very minor, diffuse effect. However, Biogen's primary focus is not liver cancer or oncolytic viruses.watch3-12m0.10
    2026-09-29Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Priority Review VoucherPrecedent for PRV monetization and valuation. Increased market awareness of PRV value could influence valuations of companies holding or pursuing PRVs.watch3-12m0.20
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/ShareIndirect impact on sector sentiment and potential M&A landscape. A strong IPO market might encourage more private companies to stay independent longer, potentially reducing the pool of acquisition targets for larger biopharma firms, or it could validate higher valuations for innovative assets, influwatch3-12m0.20
    2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseasePotential competitive pressure in the ALS market, depending on ulefnersen's efficacy and safety profile relative to existing or developing treatments.watch3-12m0.40
    2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy TherapiesIndirect competitive pressure in the ALS treatment market, particularly for FUS-ALS.watch3-12m0.30
    2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN ProgramsPotential competitive pressure in the ALS treatment market. While FUS-ALS is a specific subtype, any new ALS therapy could shift market dynamics.watch3-12m0.30
    2026-09-23Roche to Acquire Ionis Pharmaceuticals, Inc.Increased M&A activity in the neurology/rare disease space, potentially increasing valuation for similar assets or making future acquisitions more competitive.watch3-12m0.30
    2026-09-21Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and EplontersenSecond-order effect from partnership revenue loss for eplontersen, though diversified pipeline mitigates overall impact.Bearish3-12m0.20
    2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish TargetsIndirect impact through partnership agreements and potential milestone payments or royalty streams from Ionis's ASO assets.watch3-12m0.20
    2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacksEplontersen, another drug with setbacks, is partnered with Biogen. Similar to AZN, this impacts potential future revenue and milestone payments.Bearish1-3m0.30
    2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksPartnership risk. Biogen is a partner for eplontersen. Setbacks for this drug could reduce future royalty/milestone payments.Bearish3-12m0.20
    2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacksLoss of potential future milestone payments and royalties from eplontersen, which was partnered with Biogen. Reputational risk for partnership efficacy.Bearish3-12m0.30
    2026-09-18Electra Therapeutics, Inc. IPO — $350MIncreased investor attention and capital allocation towards the broader biotechnology sector, potentially leading to re-evaluation of comparable companies.watch1-3m0.30
    2026-09-17Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Telomir-Zn Preclinical Research in AMDPotential long-term competitive threat in the AMD market, though highly speculative at preclinical stage.watch1-5y0.10
    2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel PathwaysIncreased investor interest in companies with strong neuroscience and rare disease pipelines, potential for future pipeline expansion or partnerships in cardiovascular diseases.Bullish1-3m0.60
    2026-09-16Acumen Pharmaceuticals Projects Cash Runway into Early 2027Competitive landscape in Alzheimer's disease. Acumen's pipeline progress (sabirnetug) could eventually impact market share or pricing power for existing or future Alzheimer's treatments.watch3-12m0.20
    2026-09-16Acumen Pharmaceuticals, Inc. Provides Strategic Pipeline Update and Cash Runway GuidanceIndirect market sentiment and competitive landscape in Alzheimer's disease treatments.watch3-12m0.20
    2026-09-16Acumen Pharmaceuticals, Inc. Outlines Strategic Goals and Cash Runway into Early 2027Indirect competitive landscape dynamics in Alzheimer's disease. Similar to LLY, Biogen's AD portfolio (Aduhelm, Leqembi) could be marginally affected by broader market sentiment or competitive developments.watch3-12m0.10
    2026-09-16Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer TherapyIncreased investor preference for innovative oncology platforms like mRNA, potentially diverting capital from companies with less novel or slower-progressing pipelines.Bearish3-12m0.30
    2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyIncreased competition in the Spinal Muscular Atrophy (SMA) market, potential erosion of market share for Spinraza.Bearish3-12m0.60
    2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMAIncreased competition in the Spinal Muscular Atrophy (SMA) market. Isembyld is positioned as a combination therapy, potentially impacting market share or pricing power of existing SMA treatments.mixed3-12m0.40
    2026-09-13FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA TherapyIncreased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies.mixed3-12m0.40
    2026-09-13FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyPotential competitive pressure or market expansion in the SMA treatment landscape.watch3-12m0.40
    2026-09-13Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1While not a direct competitor in all immunology areas, LLY's M&A strategy for pipeline expansion (e.g., DICE, Morphic) highlights the value of innovative early-stage assets, potentially increasing M&A competition or valuation expectations for smaller biotechs.watch3-12m0.20
    2026-09-12Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A PipelineEli Lilly's successful M&A strategy in immunology could signal a more aggressive M&A environment, potentially increasing acquisition targets' valuations or creating more formidable competitors for Biogen's pipeline assets.watch1-5y0.30
    2026-09-12Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&AWhile not directly competing in all immunology sub-segments, the success of M&A in immunology by a peer like LLY could influence investor sentiment towards biotech M&A and pipeline valuation, especially for companies with immunology assets.watch3-12m0.20
    2026-09-12Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assetsEli Lilly's strategic M&A for non-GLP-1 clinical pipeline optionality, particularly in areas like neuroscience or rare diseases, could signal broader industry trends that might eventually impact Biogen's focus areas, though the direct impact is not immediate.watch1-5y0.40
    2026-09-12FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMAIncreased competition in the SMA treatment market, potential for market share shift or pricing pressure.watch3-12m0.40
    2026-09-12FDA Approves Isembyld for Spinal Muscular AtrophyIncreased competition in the SMA treatment market, potential erosion of market share for existing therapies.Bearish1-3m0.60
    2026-09-12Eli Lilly immunology division generates $2.6B in H1 revenue (+9% YoY) via M&A pushIncreased M&A activity and competition in immunology could lead to higher R&D costs or pressure on pipeline assets for companies with immunology exposure.watch1-5y0.30
    2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophyIncreased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies.mixed3-12m0.40
    2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLCPotential for future M&A activity or partnership interest in oncology assets.watch1-5y0.10
    2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS TrialsIncreased competition for existing and pipeline MS drugs, potential market share erosion.Bearish1-5y0.60
    2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS TrialIncreased competition in the multiple sclerosis market, particularly for oral therapies. Potential market share erosion for existing MS drugs.Bearish1-5y0.60
    2026-09-01Novartis Reports Positive Phase III Results for Remibrutinib in Multiple SclerosisIncreased competition in the multiple sclerosis market from a potentially superior oral BTK inhibitor could erode market share for existing and pipeline MS therapies.Bearish1-5y0.60
    2026-08-28Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for OpakalimIncreased competition in the CNS therapeutic area, particularly for neurological disorders.watch3-12m0.30
    2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimSimilar to Moderna, as a large-cap biotech with an active pipeline and history of M&A/licensing, positive sector sentiment from such deals could provide a minor uplift or reinforce valuation assumptions.watch1-3m0.20
    2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS InhibitorIndirect sector sentiment, potential for M&A activity in biotech, or strategic shifts in R&D focus for companies with significant cash reserves.watch3-12m0.20
    2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 FirmsIncreased competition in neurodegenerative disease space, potential for new therapeutic approaches to influence R&D strategies.watch3-12m0.60
    2026-08-14Replimune Group, Inc. Follow-On — $150MPotential indirect sentiment spillover within the oncology/biotech sector.watch1-3m0.20

    Continue this research

    Build your Biogen Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the BIIB entity page →

    Research Biogen Inc. · $399/mo